Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Month and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
Previous treatment with a kinase inhibitor with known activity on TRK inhibition
Unable to participate in an ongoing selitrectinib clinical trial
Medically suitable for treatment with selitrectinib
Currently enrolled in an ongoing clinical study with a TRK inhibitor